News | February 23, 2022
Biorchestra announces US$45 million series C fundraising
he financing was significantly oversubscribed with high demand from both existing and new investors.
he financing was significantly oversubscribed with high demand from both existing and new investors.
AMX0035 is an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS).
Nearly 6,000 patients have been treated with the drug since 2017
Subscribe To Our Newsletter & Stay Updated
